Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Cytokines dimerize their receptors, with binding of the “second chain” triggering signaling. In the interleukin (IL)-4/13 system, different cell types express varying levels of alternative second receptor chains (γc or IL-13Rα1), forming functionally distinct Type-I or Type-II complexes. We manipulated the affinity and specificity of second chain recruitment by human IL-4. A Type-I receptor-selective IL-4 ‘superkine’ with 3700-fold higher affinity for γc was 3-10 fold more potent than wild-type IL-4. Conversely, a variant with high affinity for IL-13Rα1 more potently activated cells expressing the Type-II receptor, and induced differentiation of dendritic cells from monocytes, implicating the Type-II receptor in this process. Superkines exhibited signaling advantages on cells with lower second chain levels. Comparative transcriptional analysis reveals that the superkines induce largely redundant gene expression profiles. Variable second chain levels can be exploited to redirect cytokines towards distinct cell subsets and elicit novel actions, potentially improving the selectivity of cytokine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The IL-4 receptor: signaling mechanisms and biologic functions
Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., & Paul, W. E. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.701 · Cited by 1,545
Cited by
Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes
Junttila, I. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00888 · Cited by 684
Self-citationCommentary: IL-4 and IL-13 receptors and signaling
McCormick, S. M., & Heller, N. M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.023 · Cited by 317
Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis
Iwaszko, M., Biały, S., & Bogunia-Kubik, K. (2021) · Cells · doi:10.3390/cells10113000 · Cited by 311
Insights into Cytokine–Receptor Interactions from Cytokine Engineering
Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304
“Instances of cytokine engineering that have successfully redirected the specificity of a cytokine to alternative receptor subunits or narrowed the specificity of a cross-reactive cytokine (68, 78, 84) are less common.”
BackgroundMethodInfluentialSelf-citationGuenova, E., Skabytska, Y., Hoetzenecker, W., Weindl, G., Sauer, K., Tham, M., Kim, K.-W., Park, J.-H., Seo, J. H., Ignatova, D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416922112 · Cited by 191
“These findings do not exclude a role for IL-12, TH1 cells, or TH1 cytokines in psoriasis but rather confirm that the therapeutic silencing of IL-23 (for example by IL-4 or newly engineered IL-4 superkines, currently under investigation) (51) is promising for psoriasis and other TH17/IL-23– associated autoimmune diseas…”
BackgroundInfectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
Recent advances in understanding the role of IL-4 signaling
Keegan, A. D., Leonard, W. J., & Zhu, J. (2021) · Faculty Reviews · doi:10.12703/r/10-71 · Cited by 154
A comprehensive kinetic model for ternary complex catalysis
Douglass Jr., E. F., & Miller, C. J. (2022) · doi:10.26434/chemrxiv-2021-wgn82-v2 · Cited by 7
Metadata
- Authors
- Junttila, I. S., Creusot, R. J., Moraga, I., Bates, D. L., Wong, M. T., Alonso, M. N., Suhoski, M. M., Lupardus, P., Meier-Schellersheim, M., Engleman, E. G., Utz, P. J., Fathman, C. G., Paul, W. E., & Garcia, K. C.
- Venue
- Nature Chemical Biology
- Published
- 2012-10-28
- Volume
- 8
- Issue
- 12
- Pages
- 990-998
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2014930718
- Cited by
- 85
- References
- 1
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.